戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s are unavoidable in evaluating chemical and drug safety.
2 edite drug development and the evaluation of drug safety.
3 explored, which poses a considerable risk to drug safety.
4 urity hampers their application in assessing drug safety.
5 hat differ in seriousness and application in drug safety.
6 tential in lead discovery, repositioning and drug safety.
7 e pharmaceutical industry in order to uphold drug safety.
8 d to ensure therapeutic efficacy and enhance drug safety.
9 s; therefore, they also play a large role in drug safety.
10 aceutical strategy to limit DILI and improve drug safety.
11  drug formulation is one approach to improve drug safety.
12 heumatoid arthritis, gout, osteoporosis, and drug safety.
13 ts of CVD, perhaps because of concerns about drug safety.
14 ession, extrapyramidal symptoms, and overall drug safety.
15 ADHD) call for scrutiny concerning long-term drug-safety.
16 tient genetic information to aid in assuring drug safety, a substantial effort is needed in both the
17  facilitates hypothesis-driven evaluation of drug safety across all prescription medications, reveali
18 ture studies should examine other regulatory drug safety actions, such as the Risk Evaluation and Mit
19  outcomes of AGILE CST-2 were to measure the drug safety and antiviral efficacy of molnupiravir in hu
20                     Tertiary end points were drug safety and compliance.
21 network studies and multisite studies assess drug safety and effectiveness in diverse populations by
22                   Uses of real-world data in drug safety and effectiveness studies are often challeng
23  is crucial for generating valid evidence on drug safety and effectiveness.
24 or engagement may have direct impacts on the drug safety and efficacy and thus are considered as CQAs
25                  Societal expectations about drug safety and efficacy are rising while productivity i
26  within, or attached to, a polymer or lipid, drug safety and efficacy can be greatly improved and new
27                                              Drug safety and efficacy due to premature release into t
28                           Because data about drug safety and efficacy in adults can rarely be extrapo
29  tool to pin down the relevant biomarker for drug safety and efficacy research.
30 ; mechanistic models of human processes; and drug safety and efficacy studies.
31 r the potential to improve the prediction of drug safety and efficacy through recapitulation of human
32 ation genetic structure in the evaluation of drug safety and efficacy, and how to relate this structu
33  of multifunctional NPs can lead to improved drug safety and efficacy, and may be complimentary to dr
34 tro to predict and validate patient-specific drug safety and efficacy, potentially enabling future cl
35 cations ranging from accelerating studies of drug safety and efficacy, to identifying pharmacological
36 al biopharmaceutical formulations to enhance drug safety and efficacy.
37 nical trials are conducted to establish both drug safety and efficacy.
38 rare and undiagnosed diseases, and improving drug safety and efficacy.
39 tion protocols and, more broadly, to improve drug safety and efficacy.
40 Ms) provide new possibilities for evaluating drug safety and efficacy.
41 s of critical concern, because it can affect drug safety and efficacy.
42 g bias in observational studies on pregnancy drug safety and explain the causal assumptions behind th
43 eassured patients and their caregivers about drug safety and helped support medication initiation.
44              Clinical staff and the funder's drug safety and medical monitoring staff had access to t
45 in using computational models for evaluating drug safety and offering a new approach to early identif
46 ring, and clinical studies investigating the drug safety and pharmacokinetics are ongoing.
47 f these transporters, which is important for drug safety and physiological studies, we developed a se
48                             The study showed drug safety and positive signs of clinical activity, pro
49 re recent advances as applied to preclinical drug safety and postmarketing surveillance with a specif
50                         Further education on drug safety and research into the underlying biological
51 e of the black-box warning system to promote drug safety and to examine the droperidol black-box warn
52                                              Drug safety and tolerability and Plasmodium falciparum r
53 al data is an important component to monitor drug-safety and this has attracted attention of many res
54 s) with unclear impacts on human physiology, drug safety, and response.
55 dverse effects in experimental drugs, and in drug safety, applicable to the evaluation of ADE signals
56 entification (MetID) procedure, essential in drug safety applications and in translational studies.
57 ve ways to communicate new information about drug safety are needed.
58                                      Current drug-safety assays for hepatotoxicity rely on biomarkers
59 ning, setting a new standard for preclinical drug safety assessment and advancing bioelectronic devic
60 d Gene (hERG) channel, which is important in drug safety assessment and commonly screened at room tem
61                                  Traditional drug safety assessment often fails to predict complicati
62  function, have implications for preclinical drug safety assessment.
63 sfy these needs through the development of a drug safety assurance information system (GeneScription)
64 ygenase-2 (COX-2) selectivity and to enhance drug safety by covalent attachment of an organic nitrate
65 er countries with active regulatory systems, drug safety can be adequately ensured, and brand-name pr
66 .2%) changes to drug labeling and 59 (14.3%) drug safety communications or other public communication
67 rious ADRs presented in BW, which is of most drug safety concern.
68  early clinical trials from poor exposure to drug safety concerns, such as drug-induced liver injury
69                       Despite concerns about drug safety, current information on older adults' use of
70                                       In the drug safety data application, the deviance information c
71 care databases can generate the age-specific drug safety data needed to inform treatment decision-mak
72                                          The drug safety database analysis of mefloquine exposure in
73                     Hoffmann-La Roche global drug safety database for the time frame 31 January 1986
74 etwork from a 2009 snapshot of a widely-used drug safety database, and used it to develop PPIN models
75                   Using the rituximab global drug safety database, we identified 231 pregnancies asso
76  should be an essential consideration during drug safety determinations, especially in pregnancy.
77 se was defined as composite understanding of drug safety, dose finding, and dose escalation.
78 y available for these novel agents regarding drug safety, effects on major cardiovascular risk factor
79                        Current paradigms for drug safety evaluation are costly, lengthy, conservative
80                    Using machine learning in drug safety evaluation can provide a more accurate and c
81                                  Duration of drug safety evaluation was 1 year or less for 26 of 34 t
82 (which most publications are focused on) for drug safety evaluation.
83 eries, suggesting limited validity to assess drug safety for pregnancy outcomes associated with prema
84                         Physicians explained drug safety in 23% of ICCs, dose finding in 52% of ICCs,
85    Thus, this sensor can be used to evaluate drug safety in a regime that the current cytotoxicity as
86   In February 2018, the Ministry of Food and Drug Safety in Korea approved tenofovir disoproxil fumar
87  paper, the first in a Series of three about drug safety in oncology, we discuss evolving challenges
88 s Series paper, the third of three papers on drug safety in oncology, we review the safety and effica
89          In view of heightening attention on drug safety in patient treatment, lipid-based nanocarrie
90 ns are an important method for disseminating drug safety information, but their impact varies.
91                                              Drug safety initiatives have endorsed human iPSC-derived
92                         Proper counseling on drug safety is crucial.
93                           Although improving drug safety is our goal and obligation to the public, FD
94 e treatments, the need for wiser handling of drug safety issues, the credibility (or lack thereof) of
95 ate abstraction levels to complement current drug safety methods.
96 tial to improve the regulatory assessment of drug safety models under the CiPA paradigm.
97 vents from the biomedical literature assists drug safety monitoring efforts.
98  of TreeScan-based approaches for systematic drug safety monitoring in pregnancy.
99 o pharmacovigilance systems could strengthen drug-safety monitoring in Uganda and other LMICs.
100 orized products on the market makes ensuring drug safety more difficult.
101 catabolites that can have a direct impact on drug safety or efficacy.
102 gned and received at least one dose of study drug; safety outcomes were assessed in all patients who
103 ere driven by concerns over side effects and drug safety, patient preference, drug availability, and
104 ble literature regarding obesity's effect on drug safety, pharmacokinetics, and dosing in obese child
105 ents who received at least one dose of study drug (safety population).
106 tive and automated screening tools to assist drug safety professionals in identifying drug-event comb
107 fy potential DDIs years in advance, enabling drug safety professionals to better prioritize their lim
108 tematic assessment of clinical presentation, drug safety profile, practical and logistical considerat
109 ages can be minimized, which may improve the drug safety profile.
110 ans use individual patient comorbidities and drug safety profiles.
111 se drug reactions were as expected given the drugs safety profiles.
112 enge in public health, especially concerning drug safety profiling and drug surveillance.
113 ccess among women included poor knowledge of drug safety, prohibitive costs, and self-treatment pract
114                 Time to first FDA postmarket drug safety-related action, a composite of withdrawals d
115 e number of patients was too small to assess drug safety reliably.
116 lth and Welfare and the Ministry of Food and Drug Safety, Republic of Korea.
117    This work was supported by the Centre for Drug Safety Science supported by the Medical Research Co
118 ligence (AI) and machine learning to improve drug safety science.
119 function relationships, ultimately advancing drug safety screening and enabling the design of safer t
120 xpanded to make an impact in drug discovery, drug safety screening for a variety of compounds and tar
121 as in vivo biological pacemaker, preclinical drug safety screening tool or ultimately as part of a ce
122 s data and to demonstrate its application to drug safety screening.
123 ources can be used to augment post-marketing drug safety signal detection.
124 We have developed an efficient and effective drug safety signal ranking and strengthening approach We
125 ally, only 13% of trials are concordant with drug safety signals, suggesting that the eligibility cri
126 o determine whether criteria correspond with drug safety signals.
127 ein, has a high probability of detecting new drug safety signals.
128 sight is less intensive, and concerns around drug safety still exist.
129 ance assessment of different methods used in drug safety studies (31, 17%).
130                              Using 2 example drug safety studies evaluated in 3 cohorts from Pennsylv
131 blishing a viable national program of active drug safety surveillance by using observational data.
132 medications and drugs of abuse using the FDA drug safety surveillance data.
133 pe and strengthening the capabilities of the drug safety surveillance system are among key FDA projec
134 ide a resource for diagnosis of DITP and for drug safety surveillance, we analyzed 3 distinct methods
135 ignificance for the drug development and the drug safety surveillance.
136 l literature can significantly contribute to drug safety surveillance.
137 ties, an important advance for hERG as a key drug safety target where traditional single-state models
138 , a Food and Drug Administration-established drug safety test.
139  disease diagnosis, risk stratification, and drug safety testing in children and adults.
140 eir application in automated high-throughput drug safety testing.
141 ing healthy and diseased cardiac biology and drug safety testing.
142                                              Drug safety tests might have to include screening for IK
143 by the Canadian Pharmacogenomics Network for Drug Safety using patients recruited from 5 adult oncolo
144                       No major difference in drug safety was observed.
145 oups who received at least one dose of study drug; safety was assessed in all patients who received a
146 tance, and laboratory chemistries reflecting drug safety were recorded.
147  particularly concerning in settings such as drug safety, where inaccuracies could lead to patient ha
148 rtain types of hallucinations and errors for drug safety, with potential applicability to other medic

 
Page Top